[高海拔地区吸入布地奈德治疗重度哮喘]

[Inhaled budesonide for severe asthma at high altitude].

作者信息

Yang S, Feng E, Suo Y

机构信息

Department of Respiratory Medicine, Fourth Hospital of PLA, Xining 810014, China.

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2000 Oct;23(10):613-6.

PMID:11372387

Abstract

OBJECTIVE

To determine the benefit of inhaled high dose budesonide combined with terbutaline in patients with severe asthma at high altitude.

METHODS

42 patients with severe asthma at high altitude were assigned in a randomized, double-blind fashion to receive either budesonide combined with terbutaline (budesonide group, 21 cases) or terbutaline with placebo (control group, 21 cases). Both groups received terbutaline delivered by a metered-dose inhaler in a dose of 2.5 mg. Budesonide delivered by a metered-dose inhaler in 1.2 mg in budesonide group and placebo managed by a specially prepared metered-dose inhaler in control group were administered after terbutaline treatment above procedures. Repeated once after 10 min. Before and after therapy, the scores of the activity of accessory respiratory muscles, dyspnea, wheezing (clinical index) and lung function were documented.

RESULTS

At 1, 2, 4, 6 h after therapy, FEV1% [(43 +/- +/- 5)%, (50 +/- 5)%, (57 +/- 5)%, (67 +/- 6)%], PEF% [(47 +/- 5)%, (55 +/- 6)%, (62 +/- 7)%, (69 +/- 7)%], clinical index (5.1 +/- 0.8, 4.3 +/- 0.6, 3.5 +/- 0.6, 2.5 +/- 0.4) in budesonide group and FEV1% [(42 +/- 5)%, (44 +/- 5)%, (45 +/- 5)%, (45 +/- 5)%], PFE% [(46 +/- 5)%, (47 +/- 5)%, (49 +/- 6)%, (49 +/- 6)%], clinical index (5.3 +/- 0.7, 5.0 +/- 0.5, 4.9 +/- 0.7, 4.8 +/- 0.7) in control group were difference markedly compared with before therapy [budesonide group was (35 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.0, and control group was (33 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.1, respectively], all (P < 0.01).

CONCLUSIONS

High dose of inhaled budesonide combined with terbutaline should be an effective therapy for patients with severe asthma at high altitude. Budesonide inhaled in high dose produces therapeutic effects as soon as 2 h after therapy.

摘要

目的

确定高海拔地区重度哮喘患者吸入大剂量布地奈德联合特布他林的疗效。

方法

42例高海拔地区重度哮喘患者采用随机、双盲方式分组，分别接受布地奈德联合特布他林治疗（布地奈德组，21例）或特布他林联合安慰剂治疗（对照组，21例）。两组均使用定量吸入器吸入2.5mg特布他林。布地奈德组在上述特布他林治疗后，使用定量吸入器吸入1.2mg布地奈德，对照组使用特制定量吸入器吸入安慰剂。10分钟后重复一次。记录治疗前后辅助呼吸肌活动、呼吸困难、喘息（临床指标）评分及肺功能情况。

结果

治疗后1、2、4、6小时，布地奈德组的第一秒用力呼气容积百分比（FEV1%）分别为[(43±5)%，(50±5)%，(57±5)%，(67±6)%]、呼气峰值流速百分比（PEF%）分别为[(47±5)%，(55±6)%，(62±7)%，(69±7)%]、临床指标分别为(5.1±0.8，4.3±0.6，3.5±0.6，2.5±0.4)；对照组的FEV1%分别为[(42±5)%，(44±5)%，(45±5)%，(45±5)%]、PFE%分别为[(46±5)%，(47±5)%，(49±6)%，(49±6)%]、临床指标分别为(5.3±0.7，5.0±0.5，4.9±0.7，4.8±0.7)，与治疗前相比均有显著差异（布地奈德组治疗前分别为(35±5)%，(38±5)%，8.3±1.0；对照组治疗前分别为(33±5)%，(38±5)%，8.3±1.1），均P<0.01。